Compare TNET & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | NRIX |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2000 | 2020 |
| Metric | TNET | NRIX |
|---|---|---|
| Price | $37.06 | $15.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $65.80 | $30.58 |
| AVG Volume (30 Days) | 518.7K | ★ 762.0K |
| Earning Date | 04-24-2026 | 04-07-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $5,010,000,000.00 | $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $26.32 |
| P/E Ratio | $11.69 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $33.67 | $8.18 |
| 52 Week High | $88.56 | $22.50 |
| Indicator | TNET | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 37.49 | 41.24 |
| Support Level | $33.67 | $14.91 |
| Resistance Level | $39.10 | $16.47 |
| Average True Range (ATR) | 1.62 | 0.81 |
| MACD | 0.82 | 0.02 |
| Stochastic Oscillator | 48.33 | 25.34 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.